mRNA Synthesis Raw Materials Industry Overview

The global mRNA synthesis raw materials market was valued at approximately USD 1.72 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 2.85% from 2024 to 2030. mRNA synthesis occurs through transcription within the cell nucleus, utilizing a DNA nucleotide sequence as a template. This synthesis involves multiple steps, including initiation, elongation, editing, and termination. The applications of mRNA synthesis are extensive, spanning drug discovery, vaccine development, and the production of therapeutics. RNA-based vaccines have gained traction due to their advantages, such as improved immunogenicity, high efficiency, and shorter production timelines. Key factors propelling the market growth include increased academic and industrial interest in mRNA technology, the advantages associated with mRNA vaccines, and rising research funding in this field.

In March 2020, the National Institute of Allergy & Infectious Diseases collaborated with Moderna, Inc. to develop mRNA-1273 (NIAID), an mRNA vaccine that demonstrated 94.1% efficacy in preventing symptomatic COVID-19. By December 2020, it received emergency use authorization from the US Food & Drug Administration (US FDA), which allowed widespread immunization. Consequently, mRNA vaccine utilization surged during the COVID-19 pandemic, highlighting the effectiveness and rapid deployment capabilities of mRNA vaccines.

Recently, multiple RNA research centers have been established to advance therapeutic applications of RNA, particularly in vitro transcribed (IVT) mRNA. Key institutions in the United States, such as the Yale Center for RNA Science and Medicine, the RNA Institute at the University of Albany, and the RNA Therapeutic Institute at the University of Massachusetts, are playing significant roles in this advancement. Additionally, university spin-offs backed by substantial venture capital—such as Argos Medicines, Factor Bioscience, CureVac, Ethris, BioNTech, Moderna, eTheRNA, and Onkaido—have driven forward preclinical and clinical development of mRNA-based therapeutics. This growing academic and industrial focus on mRNA technology is expected to heighten demand for mRNA synthesis raw materials, thereby bolstering market growth.

Moreover, the relative simplicity of mRNA vaccine manufacturing plays a significant role in the development of these vaccines. Unlike DNA, which must enter the nucleus to be transcribed into mRNA, mRNA directly initiates protein translation within the cytoplasm, bypassing the need for nuclear entry. This process not only enhances manufacturing efficiency but also reduces complexity. Unlike viral vectors or DNA, mRNAs do not integrate into the host genome but instead express the encoded protein immediately. As the mRNA is naturally degraded by cellular processes, there is no risk of insertional mutation or infection. The In Vitro Transcription (IVT) process also facilitates mRNA synthesis, offering a relatively inexpensive and rapid approach that is adaptable to various therapeutic applications. These distinct advantages of mRNA vaccines are anticipated to drive market growth over the study period.

Gather more insights about the market drivers, restrains and growth of the mRNA Synthesis Raw Materials Market

Regional Insights:

North America mRNA Synthesis Raw Materials Market Trends

• North America led the global mRNA synthesis raw materials industry in 2023, capturing over 36.77% of the total revenue, and is projected to maintain the highest compound annual growth rate (CAGR) during the forecast period.
• Key local players, like Providence Therapeutics, support the region’s market dominance by providing specialized mRNA vaccines for chronic diseases, such as cancer, which significantly contributes to revenue generation.
• Continuous innovation by regional companies is expected to drive further growth in North America’s mRNA synthesis raw materials market.

U.S. mRNA Synthesis Raw Materials Market Trends

• The U.S. is expected to witness substantial growth in its mRNA synthesis raw materials market, propelled by rising research funding, a strong presence of industry leaders, and advanced healthcare infrastructure.
• This combination of factors contributes to the U.S. maintaining a dominant share in the global market.

Europe mRNA Synthesis Raw Materials Market Trends

• Europe’s mRNA synthesis raw materials market is expanding due to the presence of established and emerging manufacturers adopting diverse organic and inorganic growth strategies.
• In April 2021, the Italian government engaged with companies like Novartis AG and Moderna, Inc. to initiate domestic mRNA vaccine production, a move expected to strengthen Europe’s market growth over the forecast period.
• United Kingdom
  • In 2023, the UK held a notable share of Europe’s mRNA synthesis raw materials market.
  • The UK government signed a strategic agreement with BioNTech in January 2023, aiming to set up research centers focused on delivering 10,000 personalized mRNA therapies by 2030. This initiative reflects the UK’s commitment to advancing mRNA technology and market growth.
• France
  • France is poised for significant market growth, bolstered by substantial investments in mRNA technology.
  • In March 2022, Sanofi committed USD 1.02 billion to establish an independent mRNA value chain in France, positioning the region as a key player in the field and expanding opportunities for market growth.
• Germany
  • Germany is expected to experience significant growth in its mRNA synthesis raw materials market over the forecast period.
  • In February 2023, BioNTech announced an investment of USD 43 million to develop an mRNA manufacturing unit, which is projected to drive market demand in Germany.

Asia Pacific mRNA Synthesis Raw Materials Market Trends

• Asia Pacific held a significant share of the global mRNA synthesis raw materials market in 2023.
• The region’s rising healthcare expenditures and investments have led many manufacturers to establish operations in Asia Pacific, contributing to regional growth.
• The COVID-19 pandemic intensified demand for mRNA vaccines, significantly expanding the market in Asia Pacific.
• China
  • China’s mRNA synthesis raw materials market is anticipated to grow steadily due to rising interest in mRNA drugs and vaccines.
  • Numerous companies, such as Blue Que Bio, Ceno Bio, and Shenxin Bio, are innovating within the field, driving market expansion.
• Japan
  • Japan’s mRNA synthesis raw materials market is set for substantial growth, with key players pursuing strategies like mergers, acquisitions, partnerships, and collaborations.
  • For example, in March 2022, Mitsui Chemicals, Inc. acquired a majority stake in NATiA, Inc., a startup focused on mRNA R&D, enhancing Japan’s competitive position.

Middle East & Africa (MEA) mRNA Synthesis Raw Materials Market Trends

• The MEA region is projected to see exponential growth in the mRNA synthesis raw materials market, aided by improving infrastructure and favorable policies from regulatory bodies.
• Rising disposable incomes and a growing elderly population are also contributing to market growth.
• Global companies, such as F. Hoffmann-La Roche Ltd, are forming partnerships, like that with Whitehead Scientific, to enter and expand in the MEA market.
• Saudi Arabia
  • Saudi Arabia’s market is anticipated to grow, supported by partnerships like that of Tabuk Pharmaceutical Manufacturing and Moderna, Inc. in June 2021, aiming to commercialize Moderna’s mRNA COVID-19 vaccine and future mRNA products in the country.
• Kuwait
  • The Kuwaiti mRNA synthesis raw materials market is expected to expand, with multinational and regional pharmaceutical firms increasing their activity, especially during winter, when demand for seasonal flu vaccines rises. This is projected to boost raw material demand in Kuwait.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global vaccine market size was estimated at USD 76.08 billion in 2023 and is expected to grow at a CAGR of 5.74% from 2024 to 2030.
• The global mRNA therapeutics market size was estimated at USD 11.75 billion in 2023 and is expected to grow at a CAGR of 17.05% from 2024 to 2030.

Key mRNA Synthesis Raw Materials Company Insights

The market players operating in the mRNA synthesis raw materials market are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key mRNA Synthesis Raw Materials Companies:

The following are the leading companies in the mRNA synthesis raw materials market. These companies collectively hold the largest market share and dictate industry trends.

• Hoffmann-La Roche Ltd.
• Jena Bioscience GmbH
• Merck KGaA
• Yeasen Biotechnology (Shanghai) Co., Ltd.
• BOC Sciences
• Thermo Fisher Scientific, Inc.
• Maravai LifeSciences
• New England Biolabs
• Creative Biogene

Order a free sample PDF of the mRNA Synthesis Raw Materials Market Intelligence Study, published by Grand View Research.